BiotechTube
CellMP

CellMP

Cambridge, United States· Est.
cellmp.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CellMP is a private, pre-revenue CDMO founded in 2020 and headquartered in Menlo Park, California, focusing exclusively on the cell therapy sector, particularly oncology. Its business model is service-based, offering end-to-end manufacturing and process development support for other companies' therapies, rather than developing its own proprietary drugs. The company operates from a single state-of-the-art facility designed to support IND-enabling studies and Phase 1/2 clinical manufacturing, positioning itself as a niche partner for emerging biotechs in the complex cell therapy space.

Oncology

Technology Platform

Integrated CDMO service platform for cell therapy, specializing in process development, scale-up, technology transfer, and GMP manufacturing for investigational products.

Opportunities

The company is positioned in the high-growth cell therapy CDMO market, where demand for specialized manufacturing capacity outstrips supply.
Its focus on early-stage, stage-appropriate support allows it to capture clients at the inception of their development journey, building long-term relationships.
Geographic location in a major biotech hub provides access to a dense pipeline of potential clients.

Risk Factors

Operational risk is high as a single-facility operation, where any disruption could impact all clients.
The company faces intense competition from larger, well-capitalized CDMOs and is vulnerable to downturns in biotech funding which directly reduce demand for its services.

Competitive Landscape

CellMP competes in the fragmented but consolidating cell therapy CDMO space. It faces competition from giant global CDMOs (e.g., Lonza, Catalent), large biopharma service providers (e.g., Thermo Fisher), and a growing number of specialized pure-play cell and gene therapy CDMOs. Its differentiation must come from superior client service, technical niche expertise, or agility in supporting early-phase programs.

More companies in Cell & Gene Therapy →More companies in United States →